Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 3Head and Neck Neoplasms 2Colorectal Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Papillomavirus Infections 1Ovarian Neoplasms 1Neoplasms 1Mouth Neoplasms 1Melanoma 1Esophageal Neoplasms 1Colonic Neoplasms 1Carcinoma in Situ 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Ipilimumab 114pembrolizumab 95Nivolumab 91aldesleukin 86Interleukin-2 57Cyclophosphamide 54Dacarbazine 52Vemurafenib 39trametinib 37Temozolomide 37incomplete Freund's adjuvant 35fludarabine phosphate 35sargramostim 32dabrafenib 32fludarabine 26Bevacizumab 26Paclitaxel 22MART-1 Antigen 21Granulocyte-Macrophage Colony-Stimulating Factor 21montanide ISA 51 20Interferon-alpha 20Cisplatin 20Carboplatin 19Sorafenib 18Introns 17Biopsy 17cobimetinib 16Radiosurgery 16atezolizumab 15Radiotherapy 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Melanoma × Indomethacin × Clear all
NCT00002535 2013-06-26

Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡